Literature DB >> 18602728

Seasonal inactivated influenza virus vaccines.

Robert B Couch1.   

Abstract

Inactivated influenza virus vaccines are the primary modality used for prevention of influenza. A system of annual identification of new strains causing illnesses, selections for vaccines, chick embryo growth, inactivation, processing, packaging, distribution and usage has been in place for decades. Current vaccines contain 15 microg of the HA of an A/H1N1, A/H3N2 and B strain and are given parenterally to induce serum anti-HA antibody for prevention of subsequent infection and illness from natural influenza. Reactogenicity is low and protection among healthy older children and adults is good; protection levels are generally lower in young children and the elderly. Needs include ensuring antigenic matches of vaccine and epidemic viruses each season, enhancing immunization rates, and providing new and improved vaccines and immunization approaches for the varied populations and circumstances globally.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602728      PMCID: PMC2643340          DOI: 10.1016/j.vaccine.2008.05.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  23 in total

1.  Influenza vaccine dosages.

Authors:  A M Palache; W E P Beyer; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

2.  The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines.

Authors:  Kristin L Nichol
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

3.  Seventeen years' experience with mineral oil adjuvant influenza virus vaccines.

Authors:  F M Davenport
Journal:  Ann Allergy       Date:  1968-06

4.  Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man.

Authors:  S R Mostow; S C Schoenbaum; W R Dowdle; M T Coleman; H S Kaye; J C Hierholzer
Journal:  Am J Epidemiol       Date:  1970-10       Impact factor: 4.897

5.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.

Authors:  K M Edwards; W D Dupont; M K Westrich; W D Plummer; P S Palmer; P F Wright
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

Review 6.  An overview of serum antibody responses to influenza virus antigens.

Authors:  R B Couch
Journal:  Dev Biol (Basel)       Date:  2003

Review 7.  Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.

Authors:  Kenneth M Zangwill; Robert B Belshe
Journal:  Pediatr Infect Dis J       Date:  2004-03       Impact factor: 2.129

8.  Viral respiratory disease at Lowry Air Force Base in Denver, 1952-1982.

Authors:  G Meiklejohn
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

9.  Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses.

Authors:  S R Mostow; S C Schoenbaum; W R Dowdle; M T Coleman; H S Kaye
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

10.  Studies with inactivated influenza vaccines purified by zonal centrifugation. 2. Efficacy.

Authors:  S C Schoenbaum; S R Mostow; W R Dowdle; M T Coleman; H S Kaye
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  45 in total

1.  Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses.

Authors:  Yolanda D Mahnke; Areej Saqr; Staci Hazenfeld; Rebecca C Brady; Mario Roederer; Ramu A Subbramanian
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

2.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

Review 3.  The influenza pandemic of 2009: lessons and implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Charurut Somboonwit; John Sinnott
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

4.  Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans.

Authors:  Kristine L Bucasas; Luis M Franco; Chad A Shaw; Molly S Bray; Janet M Wells; Diane Niño; Nancy Arden; John M Quarles; Robert B Couch; John W Belmont
Journal:  J Infect Dis       Date:  2011-02-28       Impact factor: 5.226

5.  Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans.

Authors:  Robert B Couch; Robert L Atmar; Thomas R Cate; John M Quarles; Wendy A Keitel; Nancy H Arden; Janet Wells; Diane Niño; Philip R Wyde
Journal:  Vaccine       Date:  2009-07-14       Impact factor: 3.641

6.  Rituximab-treated patients have a poor response to influenza vaccination.

Authors:  Robert A Eisenberg; Abbas F Jawad; Jean Boyer; Kelly Maurer; Kenyetta McDonald; Eline T Luning Prak; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2012-10-14       Impact factor: 8.317

Review 7.  Rationalizing the development of live attenuated virus vaccines.

Authors:  Adam S Lauring; Jeremy O Jones; Raul Andino
Journal:  Nat Biotechnol       Date:  2010-06-07       Impact factor: 54.908

8.  Models of RNA virus evolution and their roles in vaccine design.

Authors:  Samuel Ojosnegros; Niko Beerenwinkel
Journal:  Immunome Res       Date:  2010-11-03

9.  Preexisting immunity to pandemic (H1N1) 2009.

Authors:  Zheng Xing; Carol J Cardona
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

10.  Influenza in outpatient ILI case-patients in national hospital-based surveillance, Bangladesh, 2007-2008.

Authors:  Rashid Uz Zaman; A S M Alamgir; Mustafizur Rahman; Eduardo Azziz-Baumgartner; Emily S Gurley; M Abu Yushuf Sharker; W Abdullah Brooks; Tasnim Azim; Alicia M Fry; Stephen Lindstrom; Larisa V Gubareva; Xiyan Xu; Rebecca J Garten; M Jahangir Hossain; Salah Uddin Khan; Labib Imran Faruque; Syeda Shegufta Ameer; Alexander I Klimov; Mahmudur Rahman; Stephen P Luby
Journal:  PLoS One       Date:  2009-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.